Dana-Farber’s Breast Oncology Center· @DFCI_BreastOnc · X·· 17 hours agoScore60
Body · original
Tomorrow! Don’t miss Dr. Sara Tolaney (@stolaney1) at #ESMO26 as she discusses #ADC strategies in HER2-positive #BreastCancer across the first-line metastatic and early disease settings. 🗓️Friday, October 23 ⏰ 09:45 - 11:15 CEST | 3:45 - 5:15 AM EST 📍 Pamplona Auditorium, Hall 5
Heat 0 · 0 likes · 0 replies · 0 reposts
Conference abstracts
NCT05113251NCT05113251matched by - **标题 / Title：** Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
- **标题 / Title：** Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast CancerRead the abstract →Source: Dana-Farber’s Breast Oncology Center · x.com